Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

• Principais autores: Daniel Morales-Cano (Autor), Jose Luis Izquierdo-García (Autor), Bianca Barreira (Autor), Sergio Esquivel-Ruiz (Autor), Maria Callejo (Autor), Rachele Pandolfi (Autor), Palmira Villa-Valverde (Autor), Ignacio Rodríguez (Autor), Angel Cogolludo (Autor), Jesus Ruiz-Cabello (Autor), Francisco Perez-Vizcaino (Autor), Laura Moreno (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Despite increasing evidence suggesting that pulmonary arterial hypertension (PAH) is a complex disease involving vasoconstriction, thrombosis, inflammation, metabolic dysregulation and vascular proliferation, all the drugs approved for PAH mainly act as vasodilating agents. Since excessi...